NCT00264108View on ClinicalTrials.gov

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

CompletedOBSERVATIONAL
Enrollment

492

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
AnemiaNeoplasms
Interventions
DRUG

Darbepoetin alfa

Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.

DRUG

Epoetin alfa

40,000 IU once weekly, variable treatment length.

Trial Locations (20)

Unknown

's-Hertogenbosch

Amstelveen

Amsterdam

Bergen op Zoom

Den Helder

Dirksland

Ede Gld

Eindhoven

Goes

Gorinchem

Helmond

Hoofddorp

Meppel

Purmerend

Rotterdam

Spijkenisse

Tilburg

Utrecht

Winterswijk

Zeist

All Listed Sponsors
lead

Janssen-Cilag B.V.

INDUSTRY

NCT00264108 - Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia | Biotech Hunter | Biotech Hunter